An FDA advisory committee rejected AstraZeneca's proposal to use camizestrant for treating HR-positive cancer on Thursday [1].
This decision creates a setback for AstraZeneca's oncology pipeline as the regulator's panel of experts identifies a lack of clinically meaningful benefit for the drug's use in a first-line switch setting.
According to reports, the FDA's Oncologic Drugs Advisory Committee (ODAC) voted 6 to 3 [2] that the company has not demonstrated a clinically meaningful benefit for treating HR-positive cancer with the oral SERD camizestrant [2]. The committee's determination was based on the assessment that the drug does not offer a sufficient advantage over existing treatments in this specific clinical setting.
This meeting marked the end of a roughly nine-month hiatus [3] in drug-related advisory committee meetings at the FDA. The agency had planned to convene its first session of 2026 to scrutinize a pair of oncology applications from AstraZeneca.
AstraZeneca has not yet provided a public comment on the vote result. The FDA's advisory committee votes are non-binding, though they typically align with the final regulatory decision of the agency.
Because the committee's vote was 6 to 3 [2], the result suggests a significant level of disagreement among the panel members, although the majority majority a lack of evidence for the drug's efficacy in the first-line switch setting.
“The FDA's Oncologic Drugs Advisory Committee (ODAC) on Thursday voted 6 to 3 that AstraZeneca has not demonstrated its oral SERD camizestrant offers a clinically meaningful benefit”
The rejection by the FDA's advisory committee serves as a critical hurdle for camizestrant's path to approval. While the FDA's final decision is non-binding, the agency typically follows the advisory panel's recommendation. This outcome indicates that the drug may struggle to find a regulatory path for this same indication, potentially impacting AstraZeneca's oncology portfolio and competitive position in the oral SERD market.
